



Prior Authorization
JOHNS HOPKINS HEALTHCARE (MEDICAID) Growth Hormone - Priority Partners MCO
This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date. Fax signed forms to Johns Hopkins Healthcare at 1-410-424-4607 . Please contact Johns Hopkins Healthcare at 1-888-819-1043 with questions regarding the Prior Authorization process. When conditions are met, we will authorize the coverage of Growth Hormone - Priority Partners MCO.

Drug Name (specify drug) _____

Quantity	Frequency	Strength
Route of Administration	Expected Length of Therapy	

Patient Information	
Patient Name:	_____
Patient ID:	_____
Patient Group No.:	_____
Patient DOB:	_____
Patient Phone:	_____

Prescribing Physician	
Physician Name:	_____
Physician Phone:	_____
Physician Fax:	_____
Physician Address:	_____
City, State, Zip:	_____

Diagnosis: _____	ICD Code: _____
-------------------------	------------------------

Comments: _____

Please circle the appropriate answer for each question.	
1. Has the plan authorized this medication in the past for this patient (i.e., previous authorization is on file under this plan)?	<input type="checkbox"/> Y <input type="checkbox"/> N
NOTE: The use of physician samples, or manufacturer product discounts, does not guarantee coverage under the provisions of the medical and/or pharmacy benefit. All pertinent criteria must be met in order to be eligible for benefit coverage.	
[If no, skip to question 11.]	
2. Is the patient a child?	<input type="checkbox"/> Y <input type="checkbox"/> N

[If no, skip to question 8.]	
3. Is there documentation that the child is less than 18 years of age?	<input type="checkbox"/> Y <input type="checkbox"/> N
NOTE: Supporting documentation must be submitted.	
[If no, no further questions.]	
4. Is there documentation of all the following criteria: A) Growth hormone has not been effective thus far, B) Child's height is still below 5th percentile, C) Current bone age is less than 15 years for males and 14 years for females?	<input type="checkbox"/> Y <input type="checkbox"/> N
NOTE: Supporting documentation must be submitted.	
[If no, no further questions.]	
5. Does the patient meet any of the following discontinuation criteria: A) Increase in height velocity is less than two centimeters total growth in one year of therapy, B) Expected final adult height has been reached, C) there is a poor response to treatment, generally defined as increase in growth velocity of less than 50 percent from baseline in the first year of therapy, D) There are persistent and uncorrectable problems with adherence to treatment?	<input type="checkbox"/> Y <input type="checkbox"/> N
[If yes, no further questions.]	
6. Does the patient have Prader-Willi syndrome?	<input type="checkbox"/> Y <input type="checkbox"/> N
[If no, no further questions.]	
7. Has the evaluation of response to therapy taken into account whether body composition (i.e. ratio of lean to fat mass) has significantly improved?	<input type="checkbox"/> Y <input type="checkbox"/> N
[No further questions.]	
8. Is the patient an adult?	<input type="checkbox"/> Y <input type="checkbox"/> N
[If no, no further questions.]	
9. Is there documentation of follow-up monitoring for treatment efficacy with insulin-like growth factor (IGF)-1 testing being completed at least twice a year?	<input type="checkbox"/> Y <input type="checkbox"/> N
NOTE: Supporting documentation must be submitted.	
[If no, no further questions.]	
10. Is this request for a transition patient?	<input type="checkbox"/> Y <input type="checkbox"/> N
NOTE: Transition patients are defined as patients who complete growth hormone (GH) therapy for childhood onset GH deficiency and are being considered for adult GH replacement therapy. These patients must undergo retesting to determine whether the growth hormone deficiency persists. A stimulation test should be performed prior to reinstitution of growth hormone unless the member has persistent complete hypopituitarism.	
[If yes, skip to question 38.]	
[If no, no further questions.]	
11. Is the patient a child?	<input type="checkbox"/> Y <input type="checkbox"/> N
[If no, skip to question 38.]	

12. Does the patient have a documented diagnosis of growth hormone deficiency (GHD)?	<input type="checkbox"/> Y <input type="checkbox"/> N
NOTE: Supporting documentation must be submitted.	
[If no, skip to question 19.]	
13. Does the patient have a diminished growth hormone response (peak growth hormone concentration level less than 10 nanograms per milliliter) to at least two different stimulation tests?	<input type="checkbox"/> Y <input type="checkbox"/> N
NOTE: Supporting documentation must be submitted. Acceptable tests include: insulin, glucagon, clonidine, arginine, and L-dopa.	
[If yes, no further questions.]	
14. Does the patient have low insulin-like growth factor (IGF)-1 for age, sex, and pubertal status?	<input type="checkbox"/> Y <input type="checkbox"/> N
NOTE: Supporting documentation must be submitted.	
[If no, no further questions.]	
15. Is the patient 6 years of age or older?	<input type="checkbox"/> Y <input type="checkbox"/> N
[If no, no further questions.]	
16. Does the patient have a chronic disease such as malnutrition, hepatic disease, renal insufficiency, diabetes, or hypothyroidism?	<input type="checkbox"/> Y <input type="checkbox"/> N
[If yes, no further questions.]	
17. Does the patient have a height velocity (HV) less than 25th percentile (in 6-12 months prior to growth hormone (GH) therapy)?	<input type="checkbox"/> Y <input type="checkbox"/> N
[If no, no further questions.]	
18. Does the patient meet at least two of the following criteria: 1) Growth velocity less than 7 centimeters (cm) per year before 3 years old, or less than 4-5 cm per year if between 3 years old and puberty onset (Severe short stature is defined as a height more than 2 standard deviations (SD) below the population mean), 2) Delayed bone age greater than 2 SD below mean for chronological age, generally greater than 2 years delayed in patients with radiographic evidence of epiphyses not closed, 3) Documentation of a known risk factor for growth hormone deficiency (GHD), such as craniofacial anomalies, central nervous system structural abnormalities, congenital hypopituitarism, panhypopituitarism, or syndromes associated with hypopituitarism, history of hypophysectomy (surgical removal of pituitary gland), or history of central nervous system irradiation, including brain radiation?	<input type="checkbox"/> Y <input type="checkbox"/> N
NOTE: Supporting documentation must be submitted.	
[No further questions.]	
19. Does the patient have a documented diagnosis of Turner Syndrome with confirmation by karyotyping?	<input type="checkbox"/> Y <input type="checkbox"/> N
NOTE: Supporting documentation must be submitted.	

[If yes, no further questions.]	
20. Does the patient have a documented diagnosis of short stature with renal insufficiency (chronic kidney disease)?	<input type="checkbox"/> Y <input type="checkbox"/> N
NOTE: Supporting documentation must be submitted.	
[If no, skip to question 23.]	
21. Is the patient's height less than the 3rd percentile for chronological age?	<input type="checkbox"/> Y <input type="checkbox"/> N
NOTE: Supporting documentation must be submitted.	
[If no, no further questions.]	
22. Does the patient have renal insufficiency defined as serum creatinine of greater than 3.0 milligrams per deciliter, or a creatinine clearance between 5 and 75 milliliters per minute per 1.73 meters squared before renal transplant?	<input type="checkbox"/> Y <input type="checkbox"/> N
NOTE: Supporting documentation must be submitted. Post-transplant usage is not approvable.	
[No further questions.]	
23. Does the patient have a documented diagnosis of Prader-Willi Syndrome with short stature or growth failure?	<input type="checkbox"/> Y <input type="checkbox"/> N
NOTE: Supporting documentation must be submitted.	
[If no, skip to question 25.]	
24. Does the patient have severe respiratory impairment or severe obesity?	<input type="checkbox"/> Y <input type="checkbox"/> N
[No further questions.]	
25. Does the patient have a documented diagnosis of Noonan Syndrome with short stature?	<input type="checkbox"/> Y <input type="checkbox"/> N
NOTE: Supporting documentation must be submitted.	
[If no, skip to question 27.]	
26. Is the patient's height greater than 2 standard deviations below the mean for gender and age?	<input type="checkbox"/> Y <input type="checkbox"/> N
NOTE: Supporting documentation must be submitted.	
[No further questions.]	
27. Does the patient have a documented diagnosis of short stature homeobox-containing gene (SHOX) deficiency with supporting chromosome analysis?	<input type="checkbox"/> Y <input type="checkbox"/> N
NOTE: Supporting documentation must be submitted.	
[If yes, no further questions.]	
28. Does the patient have a documented diagnosis of intrauterine growth retardation (including those with Russell-Silver syndrome) or small for gestational age (SGA)?	<input type="checkbox"/> Y <input type="checkbox"/> N
NOTE: Supporting documentation must be submitted.	
[If no, skip to question 34.]	

29. Has evaluation by a pediatric endocrinologist been completed?	<input type="checkbox"/> Y <input type="checkbox"/> N
[If no, no further questions.]	
30. Is there evidence that the patient was born small for gestational age (SGA)? SGA is defined as birth weight of less than 2500 grams at a gestational age of more than 37 weeks or length below the 3rd percentile for gestational age or birth weight and/or length at least 2 standard deviations below the mean for gestational age and gender.	<input type="checkbox"/> Y <input type="checkbox"/> N
NOTE: Supporting documentation must be submitted.	
[If no, no further questions.]	
31. Is therapy being initiated between the ages of 2 and 8 years?	<input type="checkbox"/> Y <input type="checkbox"/> N
[If yes, no further questions.]	
32. Is the patient greater than 8 years of age?	<input type="checkbox"/> Y <input type="checkbox"/> N
[If no, no further questions.]	
33. Does the patient meet both of the following: 1) Child is prepubertal, 2) Therapy will be discontinued when growth velocity is less than 5 centimeters per year or there is evidence of epiphyseal fusion is present?	<input type="checkbox"/> Y <input type="checkbox"/> N
[No further questions.]	
34. Does the patient have a documented diagnosis of acquired immunodeficiency syndrome (AIDS) wasting or human immunodeficiency virus (HIV) associated failure to thrive?	<input type="checkbox"/> Y <input type="checkbox"/> N
NOTE: Supporting documentation must be submitted.	
[If no, no further questions.]	
35. Does the patient have chronic diarrhea defined as at least 2 loose stools per day for at least 30 days?	<input type="checkbox"/> Y <input type="checkbox"/> N
NOTE: Supporting documentation must be submitted.	
[If yes, no further questions.]	
36. Does the patient have chronic weakness that cannot be explained by a concurrent illness other than human immunodeficiency virus (HIV) infection?	<input type="checkbox"/> Y <input type="checkbox"/> N
NOTE: Supporting documentation must be submitted.	
[If no, no further questions.]	
37. Is the patient being simultaneously treated with antiviral agents?	<input type="checkbox"/> Y <input type="checkbox"/> N
[No further questions.]	
38. Does the patient have a documented diagnosis of growth hormone deficiency (GHD)?	<input type="checkbox"/> Y <input type="checkbox"/> N
NOTE: Supporting documentation must be submitted.	
[If no, skip to question 43.]	

39. Is there confirmation of growth hormone deficiency (GHD) with one of the following: 1) An insulin tolerance test (ITT) of less than 5 nanograms per milliliter, 2) Documentation of 3 or more pituitary hormone deficiencies?	Y N
NOTE: Supporting documentation must be submitted. ITT is contraindicated in patients with the following characteristics, so an alternative combination of arginine and growth hormone releasing hormone (GHRH) is recommended for patients 65 years of age and older, history of seizure disorders, history of ischemic heart disease or cerebrovascular disease, or abnormal electrocardiogram (EKG).	
[If yes, no further questions.]	
40. Does the patient have diminished growth hormone response (peak growth hormone concentration level less than 5 nanograms per milliliter) to at least two different stimulation tests?	Y N
NOTE: Supporting documentation must be submitted. Acceptable tests included: insulin, glucagon, clonidine, arginine, and L-dopa.	
[If no, no further questions.]	
41. Does the patient exhibit clinical symptoms such as increased weight and body fat mass with decreased lean body mass, decreased exercise capacity, decreased muscle mass and strength, reduced cardiac performance, reduced bone density and increased fracture rate, poor sleep, impaired sense of well-being, lack of motivation?	Y N
NOTE: Supporting documentation must be submitted.	
[If no, no further questions.]	
42. Does the patient meet any of the following: A) Adult onset due to hypothalamic disease, pituitary disease or surgery, or radiation therapy involving the pituitary gland, B) History of growth hormone deficiency (GHD) in childhood, C) Sheehan's syndrome (pituitary infarction), D) Autoimmune hypophysitis, E) Other hypophysitis related inflammatory conditions (sarcoidosis)?	Y N
NOTE: Supporting documentation must be submitted.	
[No further questions.]	
43. Does the patient have a documented diagnosis of acquired immunodeficiency syndrome (AIDS) wasting or human immunodeficiency virus (HIV) associated failure to thrive?	Y N
NOTE: Supporting documentation must be submitted.	
[If no, no further questions.]	
44. Does the patient have chronic diarrhea defined as at least 2 loose stools per day for at least 30 days?	Y N
NOTE: Supporting documentation must be submitted.	
[If yes, no further questions.]	

45. Does the patient have chronic weakness that cannot be explained by a concurrent illness other than human immunodeficiency virus (HIV) infection?	<input type="checkbox"/> Y <input type="checkbox"/> N
NOTE: Supporting documentation must be submitted.	
[If no, no further questions.]	
46. Is the patient being simultaneously treated with antiviral agents?	<input type="checkbox"/> Y <input type="checkbox"/> N

I attest that the medication requested is medically necessary for this patient. I further attest that the information provided is accurate and true, and that the documentation supporting this information is available for review if requested by the claims processor, the health plan sponsor, or, if applicable a state or federal regulatory agency.

Prescriber (Or Authorized) Signature and Date
--